End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
160.8 MXN | -.--% |
|
-.--% | -.--% |
Jun. 27 | Hansa Biopharma AB Announces Board Appointments | CI |
May. 31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
Sales 2024 * | 252M 23.95M 423M | Sales 2025 * | 345M 32.77M 578M | Capitalization | 3.36B 319M 5.63B |
---|---|---|---|---|---|
Net income 2024 * | -679M -64.51M -1.14B | Net income 2025 * | -693M -65.84M -1.16B | EV / Sales 2024 * | 14.9 x |
Net Debt 2024 * | 404M 38.38M 677M | Net Debt 2025 * | 815M 77.46M 1.37B | EV / Sales 2025 * | 12.1 x |
P/E ratio 2024 * |
-4.56
x | P/E ratio 2025 * |
-5.56
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
![Extreme 160.75](/images/extremecours_fleche.png)
![Extreme 160.75](/images/extremecours_fleche.png)
![Extreme 160.75](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.10% | 47.07B | |
+46.45% | 42.06B | |
-3.12% | 39.98B | |
+36.10% | 33.02B | |
-6.30% | 27.9B | |
+18.71% | 27.63B | |
+46.15% | 14.37B | |
+44.52% | 13.45B | |
+0.19% | 12.03B |
- Stock Market
- Equities
- HNSA Stock
- HNSA N Stock